Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Operations (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash from Operations for 3 consecutive years, with 14775000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 0.85% to 14775000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 76800000.0 through Dec 2025, down 39.56% year-over-year, with the annual reading at 76800000.0 for FY2025, 39.56% down from the prior year.
  • Cash from Operations for Q4 2025 was 14775000.0 at Artiva Biotherapeutics, up from 19225000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 10675000.0 in Q4 2023, with the low at 23000000.0 in Q2 2025.
  • Average Cash from Operations over 3 years is 15325500.0, with a median of 14712500.0 recorded in 2024.
  • Peak annual rise in Cash from Operations hit 0.85% in 2025, while the deepest fall reached 68.07% in 2025.
  • Over 3 years, Cash from Operations stood at 10675000.0 in 2023, then crashed by 37.24% to 14650000.0 in 2024, then dropped by 0.85% to 14775000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 14775000.0, 19225000.0, and 23000000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.